Develops oral therapies for gastrointestinal and inflammatory diseases, focusing on commercialization.
RedHill Biopharma Ltd., a specialized biopharmaceutical company, focuses primarily on gastrointestinal and infectious diseases, striving to advance innovative treatments that address significant medical challenges. The company's portfolio includes several key gastrointestinal medications tailored to meet diverse patient needs. These include Movantik, targeting opioid-induced constipation in adults with chronic non-cancer pain; Talicia, designed for the treatment of Helicobacter pylori infection in adults; and Aemcolo, aimed at managing travelers' diarrhea in adults.
In addition to its marketed products, RedHill Biopharma Ltd. is actively advancing a robust pipeline of late-stage investigational therapies. Notably, RHB-204 is undergoing Phase 3 trials for pulmonary nontuberculous mycobacteria infections, addressing a critical unmet need in respiratory medicine. The company's innovative SK2 selective inhibitor, opaganib (Yeliva), has shown promise across various indications, including severe COVID-19 pneumonia and advanced unresectable cholangiocarcinoma, with ongoing Phase 2 studies in these areas and others like prostate cancer.
Further expanding its therapeutic footprint, RedHill Biopharma Ltd. is advancing RHB-107 through Phase 2/3 trials for COVID-19 treatment, alongside investigations into its potential for advanced unresectable cholangiocarcinoma and other solid tumors. The company also has significant developments in gastrointestinal conditions, including RHB-104 for Crohn's disease, RHB-102 (Bekinda) for acute gastroenteritis and gastritis, and RHB-106, an innovative encapsulated formulation for bowel preparation currently preparing for Phase 2/3 studies. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill Biopharma Ltd. continues to push boundaries in biopharmaceutical innovation to improve patient outcomes globally.